Spinraza
·
- Prescription status not stated
- Muscles, joints and bones
- Active substance
- Nusinersen
- Used in
- Muscles, joints and bones
- Made by
- Biogen Netherlands B.V.
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Spinraza is indicated for the treatment of 5q Spinal Muscular Atrophy.
From the official label · 2026-09-30 · European Medicines Agency
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United StatesNo exact match for this strength and form
Details
| Made by | Biogen Netherlands B.V. |
|---|---|
| Active substance | Nusinersen |
| Used in | Muscles, joints and bones |
| Classification | M09 · Muscles, joints and bones |
| Orphan medicine | Yes — designated for a rare disease, according to the register |
| Authorised on | 2017-05-30 |
| Last updated by the regulator | 2026-08-04 |
| EMA product number | EMEA/H/C/004312 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).